InvestorsHub Logo
Followers 23
Posts 2120
Boards Moderated 0
Alias Born 06/21/2015

Re: sokol post# 69613

Sunday, 07/24/2016 3:12:16 PM

Sunday, July 24, 2016 3:12:16 PM

Post# of 461100
Same Dr. Hampel..

“ANAVEX 2-73 data presented today is prerequisite information in order to progress into Phase 2/3 placebo controlled studies,” said Professor Harald Hampel, MD, PhD, Professor and AXA Research Fund Chair at Sorbonne Universities’ Pierre and Marie Curie University (UPMC), Paris, France and member of Anavex’s Scientific Advisory Board. “ANAVEX 2-73’s specific molecular biology, combined with its observed favorable safety and tolerability profile makes it a very interesting candidate to explore in further clinical trials of different neurological diseases.”
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News